Researchers at Tufts University are developing a revolutionary weight loss drug that targets four gut hormones simultaneously, promising to overcome major limitations of current medications like Ozempic and Mounjaro.
These innovative tetra-functional peptides go beyond traditional treatments, which typically stimulate just one to three hormones. By activating a broader hormonal response, the new compound aims to deliver more sustainable weight loss while reducing side effects such as nausea, muscle loss, and weight regain.
“This next-generation approach could reshape obesity treatment as we know it,” said researchers leading the study.
Unlike existing drugs, which often rely on GLP-1 agonists, the new compound could offer a multi-pronged metabolic effect—enhancing satiety, energy expenditure, and insulin regulation without compromising muscle mass.
The discovery is still in the experimental stage, but early results from lab models are promising. Human trials are expected to follow within the next 12 to 18 months.
🔬 Why It Matters
With global obesity rates on the rise, safer and more effective treatments are urgently needed. If successful, this innovation could lead to next-gen therapeutics that are better tolerated, longer lasting, and less prone to rebound weight gain.
📌 Source
Tufts University | ScienceDaily | MedicalNewsToday
Comments
Post a Comment